ReviewBeilstein journal of nanotechnology2026
Nanoparticle delivery systems for HIV pre-exposure prophylaxis (PrEP): advances and challenges.
Review in Beilstein journal of nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
HIV pre-exposure prophylaxis (PrEP) encompasses antiviral drugs or formulations that aim to prevent the establishment of a permanent infection if exposure occurs. Conventional oral PrEP approaches require a daily drug regimen for effective prophylaxis, which can become burdensome, and pill fatigue creates challenges for adherence. There is, consequently, interest in the development of long-acting formulations of antiretrovirals that provide protection over extended periods of time after a single treatment. Nanoformulations and nanoparticle delivery strategies play an important role in achieving long acting (LA)-PrEP. This manuscript reviews emerging nanoparticle delivery platforms for LA-PrEP with a particular focus on four distinct classes of nanomaterials, namely, polymeric nanoparticles, lipid-based nanoparticles, inorganic nanoparticles, and hybrid nanoparticles. Nanoparticle design considerations and targeting strategies for the individual classes are examined, and the opportunities and challenges for the different nanomaterials approaches in the context of LA-PrEP are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.